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Abstract 1 
Background: Little is known about how long the Bacillus Calmette-Guerin (BCG) vaccine 2 
protects against tuberculosis (TB). We assessed its long-term vaccine effectiveness (VE).  3 
Methods: Historical cohort study based on tuberculin skin test (TST) and BCG information 4 
from participants to Norway mandatory mass TB screening and BCG vaccination programme, 5 
linked to the National TB Register, Population and Housing Censuses and the Population 6 
Register for emigrations and deaths. TST negative subjects aged 12-50 years and eligible for 7 
BCG vaccination were followed-up to the first TB episode or December 2011. The main 8 
outcomes were all and pulmonary tuberculosis. Cox regressions were used to estimate VE by 9 
time since vaccination, adjusted for age, calendar time, county-level TB rates, demographic and 10 
socio-economic indicators. 11 
Findings: Follow-up was on average over 40 years, for 83,421 unvaccinated and 297,905 BCG 12 
vaccinated subjects, with 260 TB episodes. Tuberculosis rates were 3·3 per 100,000 person-13 
years in unvaccinated and 1·3 per 100,000 person-years in vaccinated subjects. The adjusted 14 
average VE over 40-year follow-up was 49%(95%CI: 26%,65%); although the evidence was 15 
less strong after 20 years [ up to 9 years, VE =61%(95%CI: 24%,80%), 10-19 years, 16 
58%(27%,76%), 20-29 years,  38%(-32%,71%), and 30-40 years,  42%(-24,73%)]. VE against 17 
pulmonary TB for the same time intervals were respectively 67%(27%,85%), 63%(32%,80%), 18 
50%(-19%,79%) and 40%(-46%,76%).  19 
Interpretation: Findings are consistent with long-lasting BCG protection but waning of VE 20 
with time.  21 
Funding: Norwegian Institute of Public Health, and Department of Infectious Diseases 22 
Epidemiology, London School of Hygiene and Tropical Medicine 23 
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Introduction  24 
Bacillus Calmette-Guerin (BCG), the sole Tuberculosis (TB) vaccine licensed for use in human 25 
populations, is an important part of TB control efforts.1 It provides on average 86% protection 26 
against miliary and meningeal TB in children.2-4 BCG also protects against pulmonary tuberculosis 27 
(PTB), although its effect varies geographically and appears higher further from the equator, 5-7 28 
ranging for instance from no evidence of protection in the Indian TB prevention Trial up to 78% 29 
efficacy in the British MRC trial.7 Reasons for such variability, discussed elsewhere,7,8 note good 30 
efficacy if vaccination is done prior to infection with Mycobacterium tuberculosis (Mtb) or 31 
sensitization by environmental mycobacteria.7,9 BCG may also protect against TB infection,10,11 32 
suggesting a greater contribution to TB control than previously assumed, though our understanding 33 
of the immunological basis of BCG-derived protection remains limited.12 34 
BCG is one of the commonest vaccines, but the duration of effect against TB is unclear, even 35 
though this information may influence vaccination policies. The substantial decline in TB incidence 36 
in the 1980-90s led several countries to move from universal vaccination of infants (most Western 37 
European countries) or schoolchildren (e.g. United Kingdom, Norway) to targeted vaccination of 38 
infants at higher risk of TB;13 it is unclear if BCG protection will last until young adulthood when 39 
the risk of pulmonary TB and transmission to others is higher. A better understanding of long-term 40 
changes in BCG protection may also be useful not only to develop and test new TB vaccines, but 41 
also to adapt vaccination schedules. BCG-booster vaccine candidates are designed on the premises 42 
of enhancing weak or waned pre-existing BCG-derived protection.14 Other TB vaccine candidates 43 
(recombinant BCG or other attenuated) are empirically inspired or derived from BCG,14 and the 44 
performance of BCG may inform their potential effect.  45 
A recent systematic review15 suggests BCG protection may last up to 15 years. There is little 46 
information beyond that, because studies have either relatively short follow-up, or have few events 47 
if follow-up is long. The follow-up of participants to the Native American and Alaska Natives BCG 48 
trial found significant BCG protection up to 40 years after vaccination;16 although these findings 49 
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have not yet been confirmed elsewhere. We took the opportunity of an  historical population cohort 50 
from Norway on which well-preserved information on tuberculin skin testing (TST) and BCG status 51 
was available, with reliable linkage to good TB surveillance from 1962 to 2011, to assess BCG 52 
effectiveness over 40 years in the general population and a different setting. 53 
 54 
Methods 55 
Study design and population 56 
This was a historical population-based cohort study targeting TST negative subjects aged 12 to 40-57 
50 years, to whom intradermal BCG vaccination was offered as part of the mandatory nationwide 58 
Norwegian tuberculosis mass-screening programme between the late 1940s and 1975.17-19 59 
Participants were screened for tuberculosis in mobile units – including chest radiography (CXR) 60 
and tuberculin skin testing (TST) using the adrenalin von Pirquet (aP) method,18 which was 61 
standard in Norway until 2004. Screening campaigns were repeated every 2 to 10 years depending 62 
on local TB incidence. Overall attendance was 80-85%, the rest did not attend because they had 63 
been screened in other program (~5% e.g. as a miliary recruit), ill or temporary absent (5-10%) or 64 
reason unknown (~5%).17 TST negative school leavers (13-14 years) were also offered vaccination 65 
through the annual school screening program.  66 
Only Norwegian-born subjects aged 12 and over were included in the study, limited to those 67 
screened during the last round from 1962 to 1975 when data were computerized and all TB cases 68 
were compulsorily notified to a central TB Register (established 1962). We excluded subjects who 69 
had TB before or in the year of screening, and those with unknown TST and BCG status. Those 70 
aged under 12 years were not included because they were not offered BCG routinely, unless they 71 
had been in contact with a TB case. There was no specific exclusion of immunocompromised 72 
subjects; immunosuppression was not a specific contraindication for BCG vaccination as factors 73 
such as HIV infection and most immunosuppressant drugs were not yet present or widely used. 74 
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Also, there is also no clear reason why occurrence of these factors (if any) during the years of 75 
follow-up should influence TB rates in vaccinated and unvaccinated persons differently.   76 
Tuberculin testing and BCG vaccination 77 
Tuberculin skin testing by the aP method was done using Danish Old Tuberculin (OT), at a 78 
concentration corresponding to about 70% of the international standard from 1947 to 1953, and 79 
subsequently doubled from 1954 to improve sensitivity.19 A positive reaction was defined by 80 
induration ≥4mm. BCG was manufactured at the Bergen State BCG Laboratory using the Swedish-81 
Gothenburg strain.20 Liquid BCG was used until 1959, progressively replaced by freeze-dried BCG 82 
between 1959 and 1973,21 with standardization between the two formulations done by routinely 83 
comparing post-vaccination TST induration size in schoolchildren.22 From 1973 BCG was provided 84 
from Statens Serum Institute, Copenhagen. 85 
Follow-up and data sources 86 
Participants accrued person-years from entry (TST negative at screening 1962-75) until the first 87 
episode of tuberculosis, emigration, death or end of follow-up (December 2011). Tuberculosis was 88 
ascertained through linkage to the National Tuberculosis Register, and censoring by death or 89 
emigration was checked in the population register. Prophylactic treatment for Latent TB infection 90 
(LTBI) was seldom used in Norway before 2002 and was therefore not a concern. Data sources 91 
were linked directly using the Birth Number (BN), a unique 11-digit personal identifier allocated to 92 
all Norway residents at birth or immigration, and used across administrative databases. 93 
The screening database contained information on fact, date and results of CXR and TST, and BCG 94 
vaccination. BCG status was ascertained from health cards (~87%) subjects, scar examination 95 
(~7%) and self-reported vaccination history (~6%). 96 
The National Tuberculosis Register provided the TB notifications since 1962,23,24 and county-level 97 
TB-rates. Its completeness was estimated at 95% in 2008, based on crosschecking carried out since 98 
1975 with Rifampicin prescriptions and laboratory results.23,25  99 
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Census data (1960 and 1970) provided information on potential confounders, including birth date , 100 
gender and marital status, and  proxy-measures for socio-economic position (head-of-household 101 
education level and occupation, number of residents in household, urban/rural category of place of 102 
residence) at enrolment.  103 
Quantitative variables were transformed into categories: five-year average annual TB rates at 104 
county-level in 1961-6526 (proxy for local epidemiology) was classified in three levels (respectively 105 
<20, 20-25 and 26+ per 100,000); head-of-household’s education level was grouped in lower 106 
secondary or less (up to 10th grade), higher secondary (11th to 13th grade), and post-secondary, 107 
vocational or tertiary; head of household’s occupation was grouped by sectors shown to be related 108 
to TB infection risk in Norway,27 respectively manufacturing, construction, mining and blasting, 109 
technical, scientific, humanities and arts, administration/management, sales and services, 110 
agriculture, forestry and fishing, trade transportation and communication, miliary and other; 111 
household size was grouped in four categories (0-2, 3-4, 5-6, and 7+ residents). 112 
Ethical clearance was obtained from the Norwegian Research Ethics Committee.  113 
Statistical methods 114 
Hazard ratios (HRs) and 95% confidence intervals (95%CI) comparing respectively the overall and 115 
time specific (5- and 10-year intervals) TB rate in BCG vaccinated to unvaccinated subjects were 116 
computed by fitting Cox regression models to the data. Age-specific TB risk was adjusted for as a 117 
time-updated variable; demographic and socio-economic factors, and calendar time (in 10-year 118 
bands from 1960, to account for secular changes over the long follow-up) were also taken into 119 
account. Less than 3% subjects had missing data on any covariate; they were excluded from 120 
analyses. Starting with a model only including BCG status fitted on the age timescale, we added 121 
calendar time then potential confounders in turn based on descending order of magnitude of 122 
confounding at bi-variable analysis. We also checked their effects on overall vaccine effectiveness 123 
(VE) as well as any collinearity with vaccination status. Time-specific HRs were obtained by fitting 124 
an interaction between split follow-up time and BCG status. We also assessed statistical evidence of 125 
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log-linear change in HR (thus VE) between time intervals and departure from linearity. P-values 126 
were obtained using Wald and Likelihood-ratio tests as appropriate. The proportional hazard 127 
assumption was assessed graphically using Nelson-Aalen cumulative hazard plots. BCG vaccine 128 
effectiveness (VE) and 95%CI were obtained using the formula [VE(%) = (1 – HRv/u)x100]. We 129 
repeated analyses for pulmonary tuberculosis (PTB). Statistical analyses were done using Stata® 13. 130 
In this paper ‘crude’ HR/VE refer to estimates only adjusted for current age. 131 
Missing date of vaccination and sensitivity analysis: 132 
We performed two sensitivity analyses: (1) to TST stringency (by excluding subjects who 133 
developed TB in first two years after screening, likely already infected but not yet reactive to TST), 134 
and (2) to missing information on year of vaccination (missing in 18% BCG vaccinated across the 135 
database, of whom a proportion would have been vaccinated after 1962 and eligible for the study). 136 
Two approaches were used for the latter: firstly assuming all were vaccinated as soon as they 137 
reached age of eligibility and secondly, using  predictive mean matching (PMM) multiple 138 
imputation by chained equations28 (appropriate for truncated quantitative data, in our case the year 139 
of vaccination limited to 1948 to 1975 during the mass screening). Ten imputed datasets were 140 
generated using a PMM imputation model including all baseline covariates and the age-adjusted 141 
cumulative TB hazard. The analyses above were repeated on each imputed dataset restricted to 142 
eligible subjects (i.e. enrolled in 1962-75), and the imputed HRs were obtained by combining 143 
estimates across datasets using Rubin’s rules29. 144 
Role of the funding source: 145 
The sponsors of the study had no role in study design, data collection, data analysis, data 146 
interpretation, writing of the report, or approval of the manuscript of the study. The corresponding 147 
author had full access to all the data in the study and had final responsibility for the decision to 148 
submit for publication. 149 
 150 
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Results 151 
Study sample and Baseline characteristics  152 
About 77% of 1,739,996 subjects registered in the database were aged 12 to 50 years, of which 23% 153 
(306,318/1,334,686) were TST positive unvaccinated; 91·7% of TST negative were vaccinated, but 154 
the date of vaccination was missing in 18·4% (173,384/940,584). The study sample, restricted to 155 
those enrolled in 1962-75, included 83,421 TST negative unvaccinated and 297,905 BCG 156 
vaccinated subjects (figure 1). 157 
The distribution of baseline characteristics is presented in table 1. BCG vaccinated were more likely 158 
to be male and be younger at enrolment than unvaccinated. The head-of-household’s education 159 
level was also higher among vaccinated (48% higher secondary or above, vs 36% in unvaccinated), 160 
although the distribution of occupational groups were similar between groups. Finally a higher 161 
proportion of BCG vaccinated (49%) lived in households with 5 or more residents than 162 
unvaccinated (27%). The distribution of other baseline characteristics was otherwise broadly similar 163 
between groups.  164 
Median follow-ups (in years) were respectively 44 (IQR=41-46) for vaccinated and 41 (IQR=32-165 
49) for unvaccinated subjects. Censoring by emigration was negligible (<1%), and age-adjusted 166 
overall survival was comparable between groups (supplement eFigure 1). 167 
Age-adjusted TB rates were comparable across categories for most baseline characteristics 168 
(supplement eTable 1), except gender where maleTB rates were more than twice that of females 169 
(HR=2·46; 95%CI=1·67,3·62). There was no interaction between baseline variables and BCG VE, 170 
except weak evidence for education level (relatively lower VE in lower education level) and 171 
county-level TB rates (relatively lower VE in counties with incidence >25/100,000). Stratified 172 
analyses were consistent with only weak confounding by individual baseline variables (supplement 173 
eTable 2).  174 
BCG effectiveness against all tuberculosis 175 
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Overall 260 first episodes of TB were reported, of which 103 cases/3,131,917 person-years (pyrs) in 176 
unvaccinated (rate=3·3 per 100,000 pyrs), and 157 cases/12,425,272 pyrs in BCG vaccinated (crude 177 
rate 1·3 per 100,000 pyrs), corresponding to an age-adjusted HR=0·36 (0·27,0·48), and VE of 64% 178 
(52%,73%) . After adjusting for calendar time and baseline covariates, HR was 0·51 (0·35,0·74), 179 
thus an average adjusted VE of 49% (26%,65%) over 40 years (table 2). The baseline covariates 180 
had little confounding effect (supplement eTable 2), with most confounding due to calendar time.  181 
Adjusted BCG VE was 51% (7%,74%) in the first 10 years post-vaccination (61% (24%,80%) 182 
when excluding the first 2-year TB episodes), and remained 58% (27%,76%) 10-19 years post-183 
vaccination, subsequently dropping to 38% (-32%,71%) then 42% (-24,73%) respectively at 20-29 184 
and 30-40 years. There was weak evidence that change in HRs between time intervals was not log-185 
linear (p=0·015). Detailed results are presented in table 2. A further breakdown of VE in 5-year 186 
bands for the first 20 years after vaccination is provided in supplement eTable 3. Estimates 187 
remained similar, except in the first 10 years, when VE is lower at 21% (42% when excluding the 188 
first 2-year TB episodes) in the first 5 years post-vaccination, than 5-10 years (61%). 189 
The Nelson-Aalen cumulative hazard plots did not show severe deviation from the proportionality 190 
assumption (Supplement eFigure 2).  191 
BCG effectiveness against pulmonary tuberculosis 192 
The adjusted VE against PTB over 40 years was 55% (32%,70%). Effectiveness against PTB by 193 
time since vaccination were respectively 0-9 years, 57% (8%,80%) (67% (27%,85%) when 194 
excluding the first 2-year TB episodes), and 10-19 years, 63% (32%,80%). VE was 50% (-195 
19%,79%) and 40% (-46%,76%) respectively 20-29 and 30-40 years post-vaccination (figure 3; 196 
details in Supplement eTable 4). There was some statistical evidence that change in HRs between 197 
time interval was not log-linear (p=0·012). 198 
Missing date of BCG vaccination  199 
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Time specific VE estimated either assuming those with missing BCG date were vaccinated as soon 200 
as they reached the eligible age, or using PMM imputation were consistent with the complete data 201 
analysis beyond the first 10 years after vaccination. Sensitivity estimates for the first 10 years were 202 
lower and less precise than the complete data (Supplement eTables 5, 6 and 7). 203 
 204 
Discussion 205 
Our study shows that BCG on average was associated with halving the risk of TB over a 40-year 206 
period after vaccination. When examined by decades, we found that BCG was associated with 207 
about 60% reduction in the risk of TB during the first two decades after vaccination. The VE was 208 
roughly 40% between 20 and 40 years post-vaccination, albeit the evidence was less strong. The 209 
vaccine’s association with reduced risk of TB also appeared stronger against pulmonary 210 
tuberculosis, the infectious form of the disease. These results are only the second, to our knowledge, 211 
to present evidence in support of BCG protection against tuberculosis over a period of 40 years or 212 
longer, and the first in a European population. 213 
 214 
The advantages of our study included the large sample size, good documentation of the TST and 215 
BCG vaccination status, and linkage to 50 years of good routine tuberculosis surveillance and 216 
various administrative databases. The study also had limitations: relatively few  cases in each time 217 
period, due to low TB rates in Norway since the 1960s30,31 (due to an effective nationwide TB 218 
control program in the 1940-70s and improvement in living conditions);27  the lower stringency of 219 
TST compared to trials (people were tested only once at each screening round, and the aP test may 220 
have been less sensitive than the Mantoux test,32 whereas some trials used higher tuberculin doses 221 
and 2-stage testing5,7); this would cause non-differential inclusion of some TST positives and, thus 222 
underestimating vaccine efficacy. The lower VE estimate in the first 5 years is consistent with this 223 
hypothesis. The higher VE obtained when excluding TB cases in the first 2-year suggests TST 224 
sensitization was more often due to infection with Mtb than environmental mycobacteria.  225 
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There is potential for selection bias and confounding. Those who declined vaccination may have 226 
had a higher TB risk than the general population, leading to an overestimate of the VE. The 227 
information available did not support this; age-adjusted all-cause mortality and loss of follow-up 228 
through emigration were comparable to vaccinated, as were most baseline socio-demographic 229 
characteristics. The unvaccinated group was however on average older than vaccinated so likely to 230 
have been exposed to higher risk of TB earlier in their life; however, these were also subjects who 231 
remained TST negative at several successive screening rounds, and therefore more likely to be 232 
selected for lower risk of TB. We therefore consider the study underestimates BCG effectiveness. 233 
Nonetheless, we acknowledge that in our study, as in most observational studies, there is a potential 234 
for residual confounding, including from unmeasured confounders.  235 
Our estimates of BCG effectiveness in the first 5 years were lower than previously estimated in 236 
similar populations. BCG effectiveness was about 90% using data from Norway routine school 237 
vaccination programme21 although they used a case-population approach known to slightly 238 
overestimate VE. Trials in the UK, USA and Canada yielded VEs of 70-80%.5,15,33 The difference 239 
may partly be attributed to lower stringency of TST and selection through repeated screening of 240 
unvaccinated subjects at lower risk of TB, both discussed earlier; similarly low VE was reported in 241 
an earlier trial without stringent tuberculin testing prior to randomization.34 Another factor may be 242 
that revaccination may have been captured in the database as a first vaccination; revaccination was 243 
not uncommon in subjects TST negative in spite of previous vaccination.18,19 Post-vaccination TST 244 
induration is not correlated to BCG efficacy35 and the current evidence suggests that revaccination 245 
has none to at most modest boosting effect on BCG-derived immunity.36,37 In such revaccinated 246 
subjects, the VE at start of follow-up may have already declined since their first vaccination, thus 247 
underestimating VE. 248 
BCG effect beyond 5 years was consistent with literature reports from similar settings. VE 5-10 249 
years post-vaccination was comparable to estimates in cohorts from Norway21 and France,38 and 250 
consistent with the Native American16 and the British-MRC5 BCG trials. The overlap between our 251 
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estimates and these two trials continued 10-15 years post-vaccination, although the latter had higher 252 
point estimates and narrower confidence intervals, consistent stringent TST and complete case 253 
ascertainment. The other trials in the northern hemisphere above the tropic had too few TB episodes 254 
beyond 10 years to measure VE.15 The Native American trial measured BCG efficacy 15-20 years 255 
post-vaccination at 52% (28%,68%),16 the sole trial with enough data beyond 15 years. This is 256 
comparable to our present findings, as well as those of Gernez-Rieux et al. who reported VE=51% 257 
over the same interval in a French cohort.38 Overall, the VE estimated in our study over the first 20 258 
years post-vaccination appear consistent with the literature. 259 
In a recent systematic review, only the Native American trial was found to have measured BCG 260 
effectiveness beyond 20 years after vaccination.15 The 60-years follow-up measured average VE of 261 
55% (31%,77%), similar to ours over 40 years, with estimates 20-30 and 30-40 years post-262 
vaccination of about 62% (-5%,88%)16. By comparison (Supplement eFigure 3), our average VE 263 
over 40-years follow-up was 55% (32%,70%), with VE 20-30 and 30-40 years after vaccination 264 
respectively of 38% (-31%,71%) and 42% (-23%,73%). We had less power than the Native 265 
American trial beyond 20 years, because of the very high TB incidence in their trial population, but 266 
both studies found persistence of BCG protection against tuberculosis beyond 20 years after 267 
vaccination. 268 
BCG VE appeared to wane beyond the first 20 years post-vaccination, although the low study 269 
power precluded statistical evidence. A similar trend was noted in the Native American trial, and is 270 
consistent with the recent review on duration of BCG protection.15 Two hypotheses may explain 271 
decline in VE estimates with time, notably reduction in the unvaccinated subjects’ susceptibility or 272 
waning in the vaccinated subjects’ immunity. Cross-immunity from sensitization by environmental 273 
mycobacteria among unvaccinated subjects may progressively ‘mask’ persistent BCG effect, 274 
therefore giving the false impression of declining VE. The decline may also be caused by waning of 275 
BCG-derived immunological memory, one of the premises for development of BCG booster 276 
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vaccines.14 The two hypotheses are not mutually exclusive and both may have played some role in 277 
our observations.  278 
 279 
Overall, our results are consistent with the hypothesis of a long-lived BCG-derived immunity, 280 
adding to the evidence that BCG vaccination of subjects not yet infected by Mtb, nor sensitized by 281 
environmental mycobacteria, may confer some protection against tuberculosis for over 20 years.15 282 
Besides the emerging evidence that BCG may also protect against Mtb infection,10,11 a longer 283 
duration of protection would imply that the vaccine is more cost-effective than previously 284 
estimated. In the absence of any new and more effective TB vaccine, the first pillar of the World 285 
Health Organization’s (WHO) new “End TB Strategy” recognizes the potential contribution of 286 
continued BCG vaccination of individuals at higher risk of TB to their vision of a “world free of 287 
tuberculosis”,39,40; a contribution that is strengthened by BCG’s longer protection. Furthermore, 288 
given how widely BCG has been used across the world and the possibility that it may interact with 289 
future TB vaccines, it would be important to account for such long-lived effect during the 290 
development of new TB-vaccines. 291 
 292 
  293 
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Figure 1: Flowchart from the population cohort to the study sample1  
                                               
1 Broken single lines depicts excluded subjects and solid arrows are those included in analyses. The thick lines are 
subjects included in sensitivity analyses 
1,739,996 subjects with data captured 
328,856 (18.9%) aged >50 
years at screening 
29,769 (1.7%) aged <12 
years at screening  
46,685 (2.7%) TST status & 
year of screening unknown 
2,638 (0.0%) TST negative but 
BCG status unknown 
306,318 (23.0%) TST 
positive 
1,334,686 Eligible for study & Screened 
109 (0.0%) other exclusions 
85,137 (8.3%) TST 
negative Unvaccinated 
940,484 (91.7%) BCG 
Vaccinated 
1,025,621 Eligible for study and 
Tuberculin Skin Test (TST) Negative 
1,716 (2%) 
Unvaccinated with 
last screening before 
1962  
83,421 TST negative 
Unvaccinated in last screening 
round (1962-75) 
469,195 (49.9%) 
vaccinated before 
last screening round 
of 1962-75  
297,905 TST negative BCG 
vaccinated in last screening 
round (1962-75) 
173,384 (18.4%) with 
year of vaccination 
missing 
(Sensitivity Analysis 
using Multiple 
Imputation) 
 
21,358 aged <13 
years in 1962  
(Included in pragmatic 
sensitivity analysis) 
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Table 1: Baseline characteristics of study participants 
 
 BCG vaccine 
(N = 297905) 
No BCG vaccine 
(N = 83421) 
Sex   
Female (%) 163634 (55%) 54340 (65%) 
Male (%) 134271 (45%) 29081 (35%) 
Age at entry category   
12-15 years old (%) 145366 (49%)  3171 (4%) 
16-20 years old (%)  67990 (23%)  6251 (7%) 
21-30 years old (%)  29989 (10%)  5943 (7%) 
31-40 years old (%)  27217 (9%)  21315 (26%) 
41+ years old (%) 27343 (9%) 46741 (56%) 
Birth cohort (year of birth)   
1910-1919 5026 (2%) 38771 (46%) 
1920-1929 30566 (10%) 26813 (32%) 
1930-1939 25371 (9%) 7272 (9%) 
1940-1949 67809 (23%) 5930 (7%) 
≥1950 169133 (57%) 4635 (6%) 
Marital status   
Married 78321 (26%) 63932 (77%) 
Single/Other 216162 (73%) 18455 (22%) 
Missing 3422 (1%) 1034 (1%) 
Education level of head of household   
Lower secondary or less 151968 (51%) 52554 (63%) 
Higher secondary 120522 (40.6%) 27430 (33%) 
Tertiary / Vocational / Post-secondary 24383 (8%) 2652 (3%) 
Missing 1032 (0·4%) 785 (1%) 
Type of Municipality at entry (Urban/Rural)   
Rural 125580 (42%) 36765 (44%) 
Urban 171916 (58%) 46489 (56%) 
Number of residents in household at entry   
0-2 21002 (7%) 19504 (23%) 
3-4 132790 (45%) 41137 (49%) 
5-6 109416 (37%) 18292 (22%) 
≥7 34276 (11%) 4319 (5%) 
Occupation category of head of household at entry   
Manufacture, construction, mining  119232 (40%) 34571 (41%) 
Technical, scientific, humanities 24814 (8%) 4653 (6%) 
Administration, sales, services 38234 (13%) 11475 (14%) 
Agriculture, forestry, fishing 54497 (18%) 17025 (20%) 
Trade, transport, communication 49356 (17%) 13178 (16%) 
Miliary, Other 10136 (3%) 1438 (2%) 
Missing 1636 (1%) 1081 (1%) 
5-year average annual tuberculosis notification rate for 1961-65, per 100,000 person-years  
<20per100000 127961 (43%) 41976 (50%) 
20-25per100000 78637 (26%) 17310 (21%) 
≥26per100000 91300 (31%) 24135 (29%) 
Follow-up*   
Median follow-up (IQR£) (years) 44 (41-46) 41 (32-49) 
Total Follow-up (person-years) 12425273 3131918 
First TB episodes and crude rate   
# All first TB episodes (rate per 100,000 pyrs) 157 (1.3) 103 (3.3) 
# Pulmonary TB first episode (rate per 100,000 pyrs) 121 (1.0) 78 (2.5) 
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Table 2: BCG Vaccine Effectiveness against all TB 
 
Time since 
vaccination 
# TB 
cases/pyears 
Rate (per 
100,000pyears) 
‘Crude’ HR* 
(95%CI) 
Crude VE* 
(95%CI) (%) 
p-value 
 
Adjusted HR~ 
(95%CI) 
Adjusted VE~ 
(%)(95%CI) 
p-
value 
Overall         
Unvaccinated 103/3131917 3.3 (2.7;4.0) -      
BCG vaccinated 157/12425272 1.3 (1.1;1.5) 0.36 (0.27;0.48) 64 (52 to 73) <0.001 0.51 (0.35;0.74) 49 (26;65) <0.001 
0-9 years (including TB events in first 2 years after screening)    
Unvaccinated 29/812004 3.6 (2.5;5.1)       
BCG vaccinated 46/2920797 1.6 (1.2;2.1) 0.45 (0.25;0.80) 55 (20 to 75) 0.006 0.49 (0.26;0.93) 51 (7 to 74) 0.03 
0-9 years (excluding TB events occurring in first 2 years after screening) 
Unvaccinated 27/812000 3.3 (2.3;4.8)       
BCG vaccinated 36/2920781 1.2 (0.9;1.7) 0.41 (0.23;0.76) 59 (24 to 77) 0.005 0.39 (0.20;0.76) 61 (24 to 80) 0.006 
10-19 years         
Unvaccinated 44/784840 5.6 (4.2;7.5)       
BCG vaccinated 45/2874574 1.6 (1.2;2.1) 0.35 (0.21;0.58) 65 (42 to 79) <0.001 0.42 (0.24;0.73) 58 (27 to 76) 0.002 
20-29 years         
Unvaccinated 15/704774 2.1 (1.3;3.5)       
BCG vaccinated 29/2794374 1.0 (0.7;1.5) 0.72 (0.36;1.43) 28 (-43 to 64) 0.35 0.62 (0.29;1.32) 38 (-32 to 71) 0.22 
30-~40 years         
Unvaccinated 15/830300 1.8 (1.1;3.0)       
BCG vaccinated 37/3835528 1.0 (0.7;1.3) 0.72 (0.35;1.46) 28 (-46 to 65) 0.36 0.58 (0.27;1.24) 42 (-24 to 73) 0.16 
*‘Crude’ HRs are adjusted for current age (in years) (Cox model fitted on age timescale) 
~Fully adjusted for current age, calendar time, and baseline characteristics; Test for log-linear trend in HRs by timeband p=0.015 
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Figure 2: BCG Effectiveness against Pulmonary Tuberculosis by time since vaccination 
(Vertical bars represent 95% confidence intervals; TB cases occuring in first 2 years after 
screening are excluded) 
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